These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11030020)

  • 21. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of ACE inhibitor therapy in treating cardiovascular disease.
    Flint L
    Nurs Times; 2004 Mar 23-29; 100(12):34-7. PubMed ID: 15067910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How should ACE inhibitors be used in myocardial infarction?].
    Reikvam A; Madsen S
    Tidsskr Nor Laegeforen; 2000 Nov; 120(28):3413-7. PubMed ID: 11187196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension.
    Hilleman DE
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S8-11. PubMed ID: 11030017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction.
    White CM
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S18-25. PubMed ID: 11030019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [ACE-inhibitors and cardiovascular protection].
    Agabiti-Rosei E; Muiesan ML
    Cardiologia; 1994 Dec; 39(12 Suppl 1):139-47. PubMed ID: 7634257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?
    Lala A; McLaughlin MA
    Curr Hypertens Rep; 2008 Aug; 10(4):286-92. PubMed ID: 18625157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors as cardioprotective agents.
    Massie BM
    Am J Cardiol; 1992 Dec; 70(21):10I-17I. PubMed ID: 1471600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools].
    Modesti PA; Vanni S; Gensini GF
    Ital Heart J Suppl; 2003 Aug; 4(8):623-34. PubMed ID: 14655458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.